AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hosp...(ts we could both estimate the accuracy w...),Health

Date:9/28/2007

ts, we could both estimate the accuracy within a narrow confidence range and compare the AppyScore test performance to existing diagnostic methods. We believe that this study was a rigorous challenge for the test's performance in that there was a higher than expected percentage of patients with serious disease. Additionally, 1 in 3 of the evaluable patients in our study had pathology confirmed appendicitis."

Continued Mr. Donnelly, "The sensitivity of this screen test was 98% in this large study. Our study also demonstrated that a significant percentage of CT scans could potentially be avoided leading to important patient health, medical utility and cost benefits. The study showed 58% of unnecessary surgeries could have been avoided, which also further exemplifies how this new appendicitis screen testing concept can provide exciting new capabilities and benefits for emergency medicine. The high level of sensitivity also means that we could reduce the risk of sending patients home because of a false negative diagnosis. The bottom line is we believe we can help improve the standard of care for diagnosing appendicitis and deliver appreciable medical cost benefits."

The study encompassed a total of 471 individuals. Out of this total 100 were normal presumably healthy control donors. The 100 normal AppyScore control individuals were used to characterize and confirm the blood level of the proprietary biomarker used in AppyScore in normal healthy individuals. The remaining 371 were patients who presented to the emergency rooms with abdominal pain, with appendicitis as a possible diagnosis. Blood samples were collected from these 371 patients. Of these 371, 60 were not considered appendicitis candidates by ER physicians due to diagnoses based upon routine blood and urinalysis evaluation. The remaining 311 patients constituted the evaluable group of the study. These patients required further work-up according to regular care standards as suspected appendicitis ca
'/>"/>

SOURCE AspenBio Pharma, Inc. Copyright©2007 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis